British Biotech, Serono ally on inflammatory diseases
Combining British Biotech's expertise in metalloenzyme inhibition (MEI) and Serono's in multiple sclerosis and other inflammatory diseases, the companies will identify, develop, and market a treatment for inflammation. The deal could be worth $30-80mm.
- Drug Discovery Tools
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com